Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 392.93B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 18.29 |
| Forward PE | 16.80 |
| Dividend | 4.62 (2.86%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 3,119 |
| Average Volume | 2,675 |
| Open | 160.64 |
| Previous Close | 161.36 |
| Day's Range | 160.40 - 162.18 |
| 52-Week Range | 129.00 - 168.00 |
| Beta | n/a |
| RSI | 52.21 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
See Which Of The Latest 13F Filers Holds JNJ
At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 09/30/2025 reporting period, and noticed that Johnson & Johnson (Symbol: JNJ) was held by 14 of these f...
Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer . Darzalex Faspro is t...
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson's (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.
JNJ Gains FDA Nod for New DARZALEX Faspro Indication
JNJ Gains FDA Nod for New DARZALEX Faspro Indication
Johnson & Johnson: Dividends Don't Lie
Discover J&J’s latest dividend growth, Q3 earnings, and outlook. Learn what signals profit headwinds and where new innovations may offer future value.
Johnson & Johnson (JNJ) Gains FDA Approval for DARZALEX FASPRO in HR-SMM
Johnson & Johnson (JNJ) Gains FDA Approval for DARZALEX FASPRO in HR-SMM
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...
FDA Approves JNJ's Darzalex Faspro for New SMM Indication
FDA Approves JNJ's Darzalex Faspro for New SMM Indication
Johnson & Johnson gains smoldering multiple myeloma indication for Darzalex Faspro
FDA Grants Approval for Darzalex Faspro by Janssen Biotech (JNJ)
FDA Grants Approval for Darzalex Faspro by Janssen Biotech (JNJ)
VOO, JNJ, ABBV, HD: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approxima...
Johnson & Johnson (JNJ) Expands Caplyta's Use for Major Depressive Disorder
Johnson & Johnson (JNJ) Expands Caplyta's Use for Major Depressive Disorder
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
FDA Approves J&J' Caplyta As Add-On Therapy For Major Depressive Disorder In Adults
(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta as an add-on therapy with antidepressants for the treatment of major dep...
US FDA expands use of J&J's Caplyta as add-on depression drug
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAP...
Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Citi's 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fire...
Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity
Kimberly-Clark Corporation (NASDAQ: KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE: KVUE). Ordinarily, such an acquisition might mak...
Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger
Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny Kleenex maker Kimberly-Clark said on Monday it will buy Kenvue for more than $40bn in a landmark...
The multi-million pound baby powder case
Esther Addley reports on a class action suit of more than 3,000 cancer survivors and their loved ones against Johnson & Johnson ‘I remember lying on a bed,’ says Sue Rizello of her earliest memory nea...
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
Johnson & Johnson (JNJ) Seeks FDA Approval for Expanded Use of Stelara
Johnson & Johnson (JNJ) Seeks FDA Approval for Expanded Use of Stelara
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage
Broadcom, Johnson & Johnson, and Palantir headline Zacks' latest analyst picks, with AI growth, pharma innovation, and defense tech momentum driving their outlooks.